Piqray

(Alpelisib)

ApprovedSmall molecule

Alpelisib is used to treat certain types of breast cancer in women, specifically hormone receptor-positive breast cancer that has spread to other parts of the body. It works by blocking a protein that helps cancer cells grow.[2] Piqray is currently approved and in use across 16 indications[4].[1]

Piqray is one of 339 small molecule programs targeting Insulin resistance. It is currently in Approved.

Indications

Total Trials

Active Trials

338

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Insulin ResistanceRecruiting

LymphangiomaActive, not recruiting

Capillary MalformationRecruiting

Oropharynx Squamous Cell CarcinomaApproved

Breast NeoplasmActive, not recruiting

Breast CarcinomaActive, not recruiting

Vascular MalformationRecruiting

HyperglycemiaActive, not recruiting

Liver DiseaseApproved

Breast CancerTerminated

Insulin ResistancePhase 1

Recruiting

LymphangiomaPreclinical

Active, not recruiting

Capillary MalformationPhase 2

Recruiting

Oropharynx Squamous Cell CarcinomaApproved

Approved

Breast NeoplasmApproved

Active, not recruiting

Breast CarcinomaApproved

Active, not recruiting

Vascular MalformationPhase 2

Recruiting

HyperglycemiaPreclinical

Active, not recruiting

Liver DiseaseApproved

Approved

Breast CancerApproved

Terminated

Showing 10 of 16 indications

Competition

Competitive Landscape

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Piqray

Novartis

Approved

24 2

Voltaren

Novartis

Preclinical

1 3

Blenoxane

Bristol-Myers Squibb

Preclinical

1 4

Tricor

JJagotec

Preclinical

1 5

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

1 6

Bisphosphonate

Amgen

Preclinical

2 7

Tc99m Sestamibi

MM.D. Anderson Cancer Center

Preclinical

2 8

Naltrexone/bupropion

Novo Nordisk

Preclinical

1 9

Liposomal Irinotecan and Apatinib

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Preclinical

1 10

Sertraline ODT

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Vascular Malformation

NCT05983159

Phase 3Active, not recruiting

Breast Cancer

NCT05501886

Phase 1Recruiting

Insulin Resistance

NCT06354088

Q1 2027

Phase 2Active, not recruiting

Breast Neoplasms

NCT04544189

Phase 3Active, not recruiting

Breast Cancer

NCT05038735

Phase 3Active, not recruiting

Advanced Her2+breast Cancer

NCT04208178

Clinical

Trials by Indication[1]

Breast Cancer24 trials

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

Completed· Novartis logo

Novartis·Phase 2·NCT03056755·383 enrolled

Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT03207529·18 enrolled

Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer

Recruiting·SStemline Therapeutics, Inc.·Phase 1/2·NCT05563220·435 enrolled

Show 21 more trials

Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer

Completed·JJennifer Lee Caswell-Jin·Phase 2·NCT05101564·19 enrolled

Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer

Active, not recruiting·UUniversity of Kansas Medical Center·Phase 1·NCT05143229·18 enrolled

Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant

Terminated· Novartis logo

Novartis·Phase 2·NCT04899349·2 enrolled

A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer

Completed· Novartis logo

Novartis·Phase 1·NCT02058381·40 enrolled

SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast)

Active, not recruiting·BBorstkanker Onderzoek Groep·Phase 2·NCT05392608·130 enrolled

Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer

No longer available· Novartis logo

Novartis··NCT03706573

SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast Cancer

Terminated·UUNICANCER·Phase 2·NCT03386162·31 enrolled

Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors

Completed· Novartis logo

Novartis·Phase 1·NCT02077933·79 enrolled

Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer

Terminated· Sanofi logo

Sanofi·Phase 1/2·NCT03284957·136 enrolled

Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor

Recruiting·—·Phase 2·NCT05933395·135 enrolled

Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant

Terminated· Novartis logo

Novartis·Phase 2·NCT04862143·2 enrolled

Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT05967286

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

Active, not recruiting·CCriterium, Inc.·Phase 1/2·NCT05230810·40 enrolled

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

Active, not recruiting·MMarina N Sharifi·Phase 2·NCT04762979·44 enrolled

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

Active, not recruiting·CCelcuity Inc·Phase 3·NCT05501886·701 enrolled

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.

Completed· Novartis logo

Novartis·Phase 3·NCT02437318·572 enrolled

A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Patients With Hormone Receptor-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Who Progressed During or After CDK4/6 Inhibitor and Endocrine Combination Therapy

Recruiting· Roche logo

Roche·Phase 3·NCT05646862·420 enrolled

EPIK-B5: A Phase III, Randomized, Double-blind, Placebo-controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With HR-positive, HER2-negative Advanced Breast Cancer With a PIK3CA Mutation, Who Progressed on or After Aromatase Inhibitor and a CDK4/6 Inhibitor

Active, not recruiting· Novartis logo

Novartis·Phase 3·NCT05038735·210 enrolled

Targeting Insulin Feedback to Enhance Alpelisib (TIFA): A Phase 2 Randomized Control Trial in Metastatic PIK3CA-mutant Hormone-Receptor Positive Breast Cancer

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05090358·15 enrolled

A Phase IIIb, Open-label, Local, Multicenter Study of the Molecular Features of Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative Advanced Breast Cancer on First-line Treatment With Ribociclib Plus Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant (BioItaLEE)

Terminated· Novartis logo

Novartis·Phase 3·NCT03439046·287 enrolled

EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 1·NCT04188548·379 enrolled

PIK3CA-related Overgrowth Spectrum (PROS)4 trials

Study Assessing the Efficacy, Safety and Pharmacokinetics of Alpelisib in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)

Recruiting· Novartis logo

Novartis·Phase 2·NCT06997588·140 enrolled

A Phase II Study to Evaluate the Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)

Active, not recruiting· Novartis logo

Novartis·Phase 2·NCT04980833·41 enrolled

EPIK-P2: A Phase II Double-blind Study With an Upfront, 16-week Randomized, Placebo-controlled Period, to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)

Active, not recruiting· Novartis logo

Novartis·Phase 2·NCT04589650·236 enrolled

Show 1 more trial

An Open Label, Multi-center Alpelisib Roll-over Study to Assess Long-term Safety in Participants Who Have Completed a Novartis Sponsored Alpelisib (BYL719) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Alpelisib.

Not yet recruiting· Novartis logo

Novartis·Phase 2·NCT07679269·51 enrolled

Advanced Breast Cancer3 trials

A Randomized Phase III Trial of Trastuzumab + ALpelisib +/- Fulvestrant Versus Trastuzumab + Chemotherapy in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer. "ALPHABET Study".

Terminated·SSpanish Breast Cancer Research Group·Phase 3·NCT05063786·27 enrolled

A Phase II Open-label, 2-Part, Multi-center Study of BYL719 (Alpelisib) in Combination With Fulvestrant for Men and Postmenopausal Women With PIK3CA Mutation Hormone Receptor (HR) Positive, HER2-negative, Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor (AI) Treatment in Japan

Active, not recruiting· Novartis logo

Novartis·Phase 2·NCT04524000·24 enrolled

ALPelisib INdia Safety STudy (ALPINIST): A Phase IV, Prospective, Multicenter, Open-label, Non-comparative, Interventional Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR Positive, HER2-negative, Advanced Breast Cancer (aBC) With a PIK3CA Mutation, Whose Disease Has Progressed on or After Endocrine Based Treatment.

Completed· Novartis logo

Novartis·Approved·NCT05631795·40 enrolled

Insulin resistance2 trials

Alpelisib Challenge Test (ACT) for Assessment of Pancreatic β-Cell Reserve, Pilot & Feasibility Study

Recruiting·CColumbia University·Phase 1·NCT07778524·15 enrolled

Human Models of Selective Insulin Resistance: Alpelisib, Part I

Recruiting·CColumbia University·Phase 1·NCT06354088·32 enrolled

Pilot Study1 trial

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

Terminated·PPeter MacCallum Cancer Centre, Australia·N/A·NCT04801966·3 enrolled

28 more indications

Solid Tumor Malignancies1 trial

Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies

Terminated·PPamela Munster·Phase 1·NCT02620839·28 enrolled

Oropharyngeal Cancer1 trial

Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer

Terminated·UUniversity of Arizona·Phase 2·NCT03601507·9 enrolled

Squamous Cell Carcinoma1 trial

Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma

Withdrawn·PPamela Munster·Phase 1·NCT05472220

Growth1 trial

Managed Access Program (MAP) to Provide Access to Alpelisib (BYL719) for Patients With PIK3CA-Related Overgrowth Spectrum (PROS)

Available· Novartis logo

Novartis··NCT04085653

Prevention1 trial

Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients

Completed·MMedSIR·Phase 2·NCT04300790·69 enrolled

Capillary Malformation1 trial

Assessment of the Efficacy and Safety of Alpelisib (BYL719) in Pediatric and Adult Patients With Megalencephaly-CApillary Malformation Polymicrogyria Syndrome (MCAP)

Recruiting·—·Phase 2·NCT05577754·20 enrolled

Vascular Malformation1 trial

A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations

Recruiting·MMurdoch Childrens Research Institute·Phase 2·NCT05983159·50 enrolled

MPA1 trial

Compassionate Use of BYL 719 Alpelisib

No longer available·NNew Mexico Cancer Research Alliance··NCT03941782

Neoadjuvant Treatment1 trial

Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women

Completed· Novartis logo

Novartis·Phase 2·NCT01923168·340 enrolled

Immunotherapy1 trial

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Unknown status·FFondazione per la Medicina Personalizzata·Phase 2·NCT04591431·400 enrolled

Treatment1 trial

SMMART Adaptive Clinical Treatment (ACT) Trial

Withdrawn·OOHSU Knight Cancer Institute·Phase 1·NCT05238831

Hepatic Impairment1 trial

Pharmacokinetic Study of Alpelisib in Subjects With Hepatic Impairment.

Completed· Novartis logo

Novartis·Phase 1·NCT02624557·23 enrolled

Gastric Cancer1 trial

Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer

Unknown status·SSeoul National University Bundang Hospital·Phase 1/2·NCT04526470·55 enrolled

Trial1 trial

The Drug Rediscovery Protocol (DRUP Trial)

Recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT02925234·1,550 enrolled

Observational Study1 trial

Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.

Unknown status·—··NCT04852081·1,000 enrolled

Hyperglycemia1 trial

Utilizing Continuous Glucose Monitoring to Characterize and Manage Hyperglycemia in Patients Initiating Alpelisib

Active, not recruiting·HHealthPartners Institute··NCT06083038·15 enrolled

Advanced Malignant Solid Neoplasm1 trial

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05564377·2,900 enrolled

Meningioma1 trial

Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas: Phase 1 Study

Active, not recruiting·AAssistance Publique Hopitaux De Marseille·Phase 1·NCT03631953·32 enrolled

Vascular1 trial

VATCH (Vascular Anomaly Analysis for Therapy Choice): Phase II Study of Alpelisib Treatment in Subjects With TIE2/PIK3CA Pathway Driven Vascular Anomalies

Recruiting·CChildren's Hospital of Philadelphia·Phase 2·NCT07543822·61 enrolled

Ovarian Cancer1 trial

EPIK-O: A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no Germline BRCA Mutation Detected, Platinum-resistant or Refractory, High-grade Serous Ovarian Cancer

Terminated· Novartis logo

Novartis·Phase 3·NCT04729387·358 enrolled

Breast Cancer Stage IV1 trial

A ctDNA Screening Program in Patients With HR+, HER2- Metastatic Breast Cancer for Detection of High-risk Relapse Patients on Any CDK4/6 Inhibitor and a Randomised Phase II Study Comparing Alpelisib Combined With Fulvestrant to Ribociclib Combined With Fulvestrant, in Patients With Persistent Targetable PIK3CA Mutations

Terminated·UUNICANCER·Phase 2·NCT05625087·4 enrolled

Lymphatic Malformation1 trial

A Two-stage Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

Recruiting· Novartis logo

Novartis·Preclinical·NCT05948943·232 enrolled

Breast Neoplasms1 trial

A Phase II Randomized Double-blind, Placebo-controlled Study of Alpelisib in Combination With Fulvestrant for Chinese Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, PIK3CA Mutant Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor (AI) Treatment, Including a Subset With Pharmacokinetic Analysis

Active, not recruiting· Novartis logo

Novartis·Phase 2·NCT04544189·69 enrolled

Advanced HER2+Breast Cancer1 trial

EPIK-B2: A Two Part, Phase III, Multicenter, Randomized (1:1), Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation

Active, not recruiting· Novartis logo

Novartis·Phase 3·NCT04208178·19 enrolled

Metastatic Breast Cancer1 trial

A Phase 1b Open-Label Multicenter Study of OP-1250 (Palazestrant) in Combination With the CDK4/6 Inhibitor Ribociclib, With the PI3K Inhibitor Alpelisib, With the mTOR Inhibitor Everolimus, or With CDK4 Inhibitor Atirmociclib in Adult Subjects With Advanced and/or Metastatic ER Positive, HER2 Negative Breast Cancer

Active, not recruiting·OOlema Pharmaceuticals, Inc.·Phase 1·NCT05508906·190 enrolled

Triple Negative Breast Neoplasms1 trial

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation

Terminated· Novartis logo

Novartis·Phase 3·NCT04251533·137 enrolled

HNSCC1 trial

A Phase 1/2 Open-label, Biomarker-defined Cohort Trial to Evaluate the Safety, Determine the Recommended Combination Dosing, and Assess Early Antitumor Activity of Tipifarnib and Alpelisib for the Treatment of Adult Participants Who Have HRAS-overexpressing and/or PIK3CA-mutated and/or - Amplified Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Completed·KKura Oncology, Inc.·Preclinical·NCT04997902·45 enrolled

Anatomic Stage I Breast Cancer AJCC v81 trial

A Phase-2, Two-Cohort Trial of Neoadjuvant Nab-Paclitaxel and Alpelisib in Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT04216472·6 enrolled

Regulatory

FDA Approval Timeline[5]

May 24, 2019

PIQRAY

NDA NDA212526

Sep 1, 2020

PIQRAY

NDA NDA212526

Jul 20, 2021

PIQRAY

NDA NDA212526

Apr 5, 2022

VIJOICE

NDA NDA215039

May 4, 2022

PIQRAY

NDA NDA212526

Nov 22, 2022

PIQRAY

NDA NDA212526

Jan 18, 2024

PIQRAY

NDA NDA212526

Apr 24, 2024

VIJOICE

NDA NDA218466

Sources

References

[1]
ClinicalTrials.gov — 62 trial records for Alpelisib. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Piqray drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Alpelisib compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Alpelisib. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA218466). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Piqray. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: PI3-Kinase P110-Alpha Subunit Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Novartis

Patent Landscape[6]

Patent Cliff

Sep 10, 2029

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8476268Sep 10, 2029

8227462Apr 29, 2033

12427141Feb 17, 2037

11433059Feb 17, 2037

Piqray

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Trials by Indication[1]

Breast Cancer24 trials

PIK3CA-related Overgrowth Spectrum (PROS)4 trials

Advanced Breast Cancer3 trials

Insulin resistance2 trials

Pilot Study1 trial

Solid Tumor Malignancies1 trial

Oropharyngeal Cancer1 trial

Squamous Cell Carcinoma1 trial

Growth1 trial

Prevention1 trial

Capillary Malformation1 trial

Vascular Malformation1 trial

MPA1 trial

Neoadjuvant Treatment1 trial

Immunotherapy1 trial

Treatment1 trial

Hepatic Impairment1 trial

Gastric Cancer1 trial

Trial1 trial

Observational Study1 trial

Hyperglycemia1 trial

Advanced Malignant Solid Neoplasm1 trial

Meningioma1 trial

Vascular1 trial

Ovarian Cancer1 trial

Breast Cancer Stage IV1 trial

Lymphatic Malformation1 trial

Breast Neoplasms1 trial

Advanced HER2+Breast Cancer1 trial

Metastatic Breast Cancer1 trial

Triple Negative Breast Neoplasms1 trial

HNSCC1 trial

Anatomic Stage I Breast Cancer AJCC v81 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Patent Landscape[6]

Related News